Report cover image

Chronic Periodontitis - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679390

Description

Chronic Periodontitis - Pipeline Insight, 2024



DelveInsight’s, “Chronic Periodontitis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Periodontitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Chronic Periodontitis: Understanding

Chronic Periodontitis: Overview

Periodontal disease and dental caries are the most common diseases in the oral cavity. Chronic periodontitis is one of the periodontal diseases. It is a long-lasting inflammatory disease affecting the soft and hard tissues around the teeth and it is common worldwide. This disease is related to common and preventable biological risk factors (e.g., high blood pressure, high blood cholesterol, diabetes, genetic factors, and obesity) and behavioral risk factors (e.g., an unhealthy diet, physical inactivity, and tobacco use). Chronic periodontitis is ideally diagnosed at the beginning of the disease.

""Chronic Periodontitis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Periodontitis pipeline landscape is provided which includes the disease overview and Chronic Periodontitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Periodontitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Periodontitis R&D. The therapies under development are focused on novel approaches to treat/improve in Chronic Periodontitis.
This segment of the Chronic Periodontitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Periodontitis Emerging Drugs
  • ST 266: Noveome
ST266 is a cell-free biologic made by culturing a novel population of human amnion-derived cells. Through a proprietary culturing method, these cells produce an array of growth factors and cytokines, known as the secretome, which promote cellular survival and reduce inflammation.

Further product details are provided in the report……..

Chronic Periodontitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Periodontitis drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Chronic Periodontitis
There are approx. 10+ key companies which are developing the therapies for Chronic Periodontitis. The companies which have their Chronic Periodontitis drug candidates in the most advanced stage, i.e. Phase II include, Noveome
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Chronic Periodontitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intravenous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Peptide
  • Protein
  • Propylene glycols
  • Cell Therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Periodontitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Periodontitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Periodontitis drugs.

Chronic Periodontitis Report Insights
  • Chronic Periodontitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Chronic Periodontitis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Chronic Periodontitis drugs?
  • How many Chronic Periodontitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Periodontitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Periodontitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Periodontitis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Amyndas Pharmaceuticals
  • Takeda
  • CSL behring
  • Vaxcyte
  • Noveome
  • Perioc
Key Products
  • AMY 101
  • GXV 003
  • Research programme: periodontitis vaccines
  • VAX PG
  • ST 266
  • Ciclosporin topical gel

Table of Contents

60 Pages
Introduction
Executive Summary
Chronic Periodontitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Periodontitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase II)
Comparative Analysis
Ciclosporin topical gel: Perioc
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
VAX PG: Vaxcyte
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Periodontitis Key Companies
Chronic Periodontitis Key Products
Chronic Periodontitis- Unmet Needs
Chronic Periodontitis- Market Drivers and Barriers
Chronic Periodontitis- Future Perspectives and Conclusion
Chronic Periodontitis Analyst Views
Chronic Periodontitis Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us